Alkermes Plc is driven by a strong set of values and corporate philosophy. The company places emphasis on innovation, collaboration, and a patient-centered approach. Alkermes is committed to developing groundbreaking therapies and technologies to improve the lives of people with serious and complex medical conditions. With a focus on research excellence, they strive to bring forward solutions that address unmet medical needs. Alkermes values integrity, transparency, and accountability in all aspects of their work. By investing in their employees, fostering a diverse and inclusive culture, and engaging with stakeholders, Alkermes Plc aims to make a lasting positive impact in the healthcare industry.

Alkermes Plc is primarily present in the United States.

Some significant milestones achieved by Alkermes Plc include the approval of VIVITROL for the prevention of opioid relapse, the launch of ARISTADA for the treatment of schizophrenia, and the acquisition of Elan Drug Technologies. Furthermore, the company also secured FDA approval for BYDUREON BCise, a once-weekly treatment for type 2 diabetes, and expanded its product portfolio through collaborations and partnerships. Alkermes Plc has consistently focused on developing innovative therapies and entering strategic alliances to address unmet medical needs, establishing itself as a leading biopharmaceutical company in the industry.

Alkermes Plc is a pharmaceutical company with a rich history and strong background. Established in 1987, Alkermes has grown to become a leading biopharmaceutical firm specializing in the development and manufacturing of innovative medicines. The company is committed to making a difference in the lives of patients suffering from serious diseases, such as central nervous system (CNS) disorders and addiction. With a focus on research and development, Alkermes has successfully brought several FDA-approved therapies to market. By leveraging its expertise in drug delivery technologies, the company continues to advance its pipeline of potential treatments. Alkermes Plc is dedicated to improving health outcomes and reshaping the future of medicine.

The main competitors of Alkermes Plc in the market are AstraZeneca, Johnson & Johnson, Novartis, and Pfizer.

Alkermes Plc is primarily active in the biopharmaceutical industry.

The business model of Alkermes Plc is focused on the development and commercialization of innovative pharmaceutical products to address unmet medical needs. Alkermes is dedicated to providing solutions for patients through advanced drug delivery technologies, extensive research and development, and strategic partnerships. The company specializes in areas such as neuroscience, addiction medicine, and oncology, aiming to improve the lives of individuals suffering from a range of diseases and disorders. Alkermes Plc strives to create value for shareholders by delivering effective therapies while maintaining a strong commitment to scientific excellence and regulatory compliance.

Alkermes Plc의 P/E 비율은 23.38입니다.

Alkermes Plc의 P/S 비율은 3.5입니다.

Alkermes Plc에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Alkermes Plc 매출은 1.45 조. USD입니다.

예상되는 Alkermes Plc 이익은 216.92 백만 USD입니다.

Alkermes Plc is a leading company in the biopharmaceutical industry that specializes in researching, developing, and marketing drugs for the treatment of central nervous system disorders and addiction disorders. The company is headquartered in Dublin, Ireland and has global subsidiaries. The company divides its business activities into two segments: Commercial and R&D. The Commercial segment focuses on marketing drugs used for the treatment of addiction disorders such as alcohol dependence, opioid dependence, and smoking cessation. The R&D segment is dedicated to the discovery and development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, bipolar disorders, Alzheimer's, and multiple sclerosis. The company's key products include Vivitrol, Aristada, Risperdal Consta, and Ampyra. Vivitrol is the only long-acting medication approved by the US Food and Drug Administration (FDA) for treating both alcohol dependence and opioid dependence. Aristada is an injectable long-acting antipsychotic used for the treatment of schizophrenia. Risperdal Consta is a long-acting antipsychotic used for the treatment of schizophrenia and manic episodes in bipolar disorder. Ampyra is a potassium-optimized medication used for improved walking ability in patients with multiple sclerosis. In 2019, the company generated $1.17 billion in revenue. The majority of these earnings come from the sales of Vivitrol, Aristada, and Risperdal Consta. Additionally, Alkermes Plc has numerous partnerships with other companies to combine technology and research findings and develop new compounds. Overall, Alkermes Plc's business model is focused on developing and marketing innovative medications for the most common central nervous system disorders and addiction disorders. The company has a strong pipeline of product candidates focused on discovering and developing new therapies to improve clinical outcomes. Alkermes Plc has a strong market position and has the potential to further expand over time as it grows its global reach through partnerships and acquisitions.

Alkermes Plc은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Alkermes Plc의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Alkermes Plc의 ISIN은 IE00B56GVS15입니다.

Alkermes Plc의 WKN은 A1JKVH입니다.

Alkermes Plc의 티커는 ALKS입니다.

지난 12개월 동안 Alkermes Plc은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Alkermes Plc은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Alkermes Plc의 현재 배당 수익률은 입니다.

Alkermes Plc은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Alkermes Plc은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Alkermes Plc은 '건강' 섹터에 속합니다.

Alkermes Plc의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Alkermes Plc는 0 USD를 배당금으로 지급했습니다.

Alkermes Plc의 배당금은 USD에 지급됩니다.